← Back to Clinical Trials
Recruiting NCT06858709

Effect of Adding Electroacupuncture to Anti-cancer Therapy-induced Peripheral Neuropathy

Trial Parameters

Condition Chemotherapy-induced Peripheral Neuropathy (CIPN)
Sponsor Zhongnan Hospital
Study Type INTERVENTIONAL
Phase N/A
Enrollment 150
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2025-03-20
Completion 2027-01-15
Interventions
True acupuncture + standard anti chemotherapy-induced peripheral neuropathy treatmentSham acupuncture +standard anti chemotherapy-induced peripheral neuropathy treatment

Brief Summary

This study is being done to evaluate the potential benefits of using electroacupuncture to reduce the severity of chemotherapy-induced peripheral neuropathy for patients with peripheral neuropathy after chemotherapy.

Eligibility Criteria

Inclusion Criteria: * 18 years of age or older, of any nationality. * Patients diagnosed with malignant tumor. * Eligible patients will report altered sensations and/or pain and/or other neurological symptoms, with a grade between 2-3 for chemotherapy-induced peripheral neuropathy on the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events-version 5.0 (NCI-CTCAE.v-5.0). * Predicted life expectancy of ≥3 months. * Intact skin without any breaches or purulent discharge. * Written informed consent by the patient before enrolment Patients must be able to comply with the study protocol, which includes attending the treatment sessions on time and completing the study questionnaires in accordance with the study protocol. Exclusion Criteria: * History of pre-existing peripheral neuropathy before chemotherapy, including alcoholism, vitamin B deficiency, diabetes, HIV, congenital neuropathy, and toxic neuropathy. * Patients with skin damage, pus or scar at the acupuncture

Related Trials